Google
INCY 株価分析 — Incyte Corporation (Healthcare >> Biotechnology)
INCY に関するよくある質問
INCYのPER（株価収益率）は？
Incyte Corporation（INCY）は現在PER 15.46倍で取引されています。
INCYのROE（自己資本利益率）は？
Incyte CorporationのROEは25.41%です。
INCYの配当利回りは？
Incyte Corporationの配当利回りは0.00%です。
INCYの品質スコア（Quality Score）は？
当社のAIはINCYの総合財務品質を100点中100点と評価しています。収益性・成長性・負債・利益の安定性に基づく評価です。
INCYは今が買い時ですか？
当社AIのタイミングスコアは100点中87点で、テクニカル指標とモメンタムから見た現在価格の相対的な魅力度を示します。
INCYはどのセクターに属しますか？
Incyte CorporationはHealthcare >> Biotechnologyセクターに分類されます（NASDAQ市場）
INCY AI Analysis Summary
Our AI summary for INCY: Incyte Corporation (NASDAQ), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 15.46, ROE of 25.41%, a dividend yield of 0.00%. Its financial Quality Score stands at 100/100 — fundamentals stronger than most of the market. The AI Timing Score is 87/100 — multiple technical signals currently support price momentum. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.
|
USD 119.52
Price
-3.47
(-2.82%)
Day Change
|
|
|---|
INCY, ファンダメンタルスコアはexcellent ( ファンダメンタル = 100) そして テクニカルスコアは ...(Sign In to See)...
Loading chart...
- Signal
- OUTPERFORM
- Signal Description
- Company financial health is Excellent
- Reason
-
Company financial health is Excellent from almost all quality indicators
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Momentum indicators aligned on the daily timeframe
In details, quality factors are not quite good , financial health is not quite good , and ability to make profit is good , ...
| Deepscope 分析 |
|
58% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.12 From 30 days period |
| News Score | N/A |
| Magic Formula Rank by ROA |
418
|
| Magic Formula Rank by ROE |
418
|
| Magic Formula Rank by ROIC |
394
|
| Price | 119.52 |
| PBV / Sector |
3.93 / 5.20
|
| Earning Per Share | 7.73 |
| PE / Sector |
15.46 / 19.97
|
| PEG or PE/Growth / Sector |
0.01 / 1.22
GREAT
|
| Average 1M Daily Value |
219.55 M
GREAT
|
| Average 1W Daily Value |
392.72 M
GREAT
|
| Timing Factors |
|
71% |
| Financial Health |
|
52% |
| ポイントになる統計 |
|
75% |
| 配当 |
|
4% |
| 登録情報 |
| Analyze Date | 2026-08-01 08:00:01 |
| Symbol | INCY |
| Name | INCYTE CORPORATION |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 202.70 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 24,929.80 / 9,903.94 |
| ニュース |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 1801 Augustine Cut-Off, Wilmington, DE, United States, 19803
Phone: 302 498 6700
Website: https://www.incyte.com
Employees: 2,844
Sector: Healthcare >> Biotechnology
Description: Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan. The company offers JAKAFI for the treatment of myelofibrosis (MF), polycythemia vera, and steroid-refractory acute graft-versus-host disease; ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; MONJUVI/ MINJUVI for the treatment of diffuse large B-cell lymphoma and Follicular Lymphoma; NIKTIMVO for the treatment of chronic graft-versus-host disease. It also provides INCA033989 for the treatment of essential thrombocythemia and MF; INCA035784 for the treatment of anti-mutant calreticulin and myeloproliferative neoplasms (MPNs); INCB160058 for the treatment of MPNs; PEMAZYRE, a selective fibroblast growth factor receptor kinase inhibitor for the treatment of unresectable biliary tract cancer, metastatic cholangiocarcinoma, and myeloid/lymphoid neoplasms; ZYNYZ to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma. The company's clinical stage products include INCB123667 for ovarian cancer; INCB161734 for solid tumors; INCA33890 for cancers; Ruxolitinib cream for atopic dermatitis, hidradenitis suppurativa (HS), and prurigo nodularis; Povorcitinib for HS, nonsegmental vitiligo, prurigo nodularis, and asthma; and INCB00928 for the treatment of fibrodysplasia ossificans progressive. It has collaboration and license agreement with Novartis, Lilly, and Syndax. The company sells its products to specialty and retail pharmacies, hospital pharmacies, and distributors. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation was incorporated in 1991 and is headquartered in Wilmington, Delaware.
Analyst Ratings & Target Price
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
